Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Aziz-Bose R, Wachter F, Chiarle R, Lindeman NI, Kim AS, Degar BA, et al. Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. Blood Adv. 2022;6(9):2893-2896.

Bae S, Oh B, Tsai J, Park PS, Greenblatt MB, Giannopoulou EG, et al. The crosstalk between MYC and mTORC1 during osteoclastogenesis. Front Cell Dev Biol. 2022;10:920683.

Moscat J, Linares JF, Duran A, Diaz-Meco MT. Protein kinase Cλ/ι in cancer: a contextual balance of time and signals. Trends Cell Biol. 2022;32(12):1023-1034.

Butler-Laporte G, Povysil G, Kosmicki JA, Cirulli ET, Drivas T, Furini S, et al. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. PLoS Genet. 2022;18(11):e1010367.

Brady NJ, Barbieri CE. JAK inhibition shows two faces in prostate cancer. Nat Cancer. 2022;3(9):1021-1023.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Grossman ME, Cohen M, Ravits M, Blume R, Magro CM. Cutaneous collagenous vasculopathy: A report of three cases. J Cutan Pathol. 2022;49(5):491-495.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.

Alhomoud M, Williams A, Magro C, Van Besien K, Vesole DH, Laurence J. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma. 2022;63(2):473-477.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022;20(5):673-685.